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The idea of combining drugs and diagnostics in oncology is not
new. When the selective estrogen-receptor modulator tamoxifen
was developed in the 1970s for the treatment of breast cancer, data
on estrogen-receptor status were correlated with the treatment
outcome. Based on a phase II study performed in patients with
advanced breast cancer, published in 1976, the investigators con-
cluded:“a high degree of correlation between response and positive
estrogen-receptor assay suggests the value of the diagnostic test as
a means to select patients for tamoxifen treatment” (1). Despite
the fact that this conclusion was drawn nearly 40 years ago, the
adaptation of the drug-diagnostic co-development model has been
relatively slow and it is only within the last decade that it has gained
widespread acceptance. The parallel development of the mono-
clonal antibody trastuzumab (Herceptin®, Roche/Genentech) and
the companion diagnostics (CDx) assay for HER2 protein overex-
pression (HercepTest™, Dako) in the 1990s seems to have served
as an inspiration to the pharma and biotech companies (2, 3), and
the number of drug-diagnostic co-development projects within
oncology has increased rapidly within the last decade.
Genomic sequencing has shown that marked heterogeneity
exists in cancer, both between and within patients, which mean
that “standard” treatments seldom work for everyone (4). The
taxonomy of classifying the cancer diseases, according to their
sites of origin and histology, also seems to be far from opti-
mal when it comes to the treatment decision. The philosophy
of “one-disease-one-target-one drug” is history and the improve-
ment in cancer pharmacotherapy must come from an increased
understanding of the underlying molecular mechanisms in the
individual patient. These mechanisms are of a complex nature
and we are far from a complete understanding. However, what we
do understand is that drugs work at the molecular level, and it is
here that we must seek the solution to a more rational drug devel-
opment process and the subsequent treatment of the patients in
the clinic (5). Molecular diagnostic testing has provided us with an
increased understanding of the cancer biology, which has recently
enabled the development of molecular-based targeted therapies
such as vemurafenib (Zelboraf®, Roche/Genentech) for melanoma
patients harboring a BRAF V600E mutation (6), and crizotinib
(Xalkori®, Pfizer) and ceritinib (Zykadia®, Novartis), for non-small
cell lung cancer (NSCLC) patients with EML4–ALK transloca-
tion (7, 8). For the latter two compounds, crizotinib and ceritinib,
the development time has been remarkably short, which would
never have happened without an in-depth molecular understand-
ing of the disease biology and the mechanism of action of the
drugs.
The present research topic of Frontiers in Oncology aims to
provide an update on the wide-ranging area of drug-diagnostic
co-development, biomarker research, and CDx. The research topic
covers both basic scientific aspects as well as the clinical and regu-
latory challenges through a number of Review, Original Research,
and Clinical Case Study articles. In the review by Olsen and Jør-
gensen, an introduction to the subject is given and here both the
drug-diagnostic co-development model as well as the clinical and
regulatory challenges related to CDx development is discussed (9).
The first CDx to obtain approval by the US Food and Drug
Administration (FDA) was the assay for HER2 overexpression
(HercepTest™, Dako) based on immunohistochemistry (IHC).
IHC is a frequently applied method for protein expression analysis
in tumor tissue, and despite the current great focus on gene-
based assays, especially next-generation sequencing (NGS), this
method is still recognized as an important supplement to analy-
sis of different type of gene aberrations. Likewise, there seems
to be cancer-related changes in the proteins that are not directly
reflected in the changes in RNA and DNA. Gremel et al. review
the currently applied CDx tests based on IHC but points also
toward the future with regard to mutation-specific antibodies,
in situ proximity legation assays, and alternative protein binders
such as aptamers (10).
Several articles in this research topic touch upon NGS in rela-
tion to CDx, but Pant et al. provide the most comprehensive review
(11). In this review, the authors exhaustively discuss the different
platforms, sequencing technologies, bioinformatics, data report-
ing, regulatory aspects as well as the potential use of the technology
in relation to drug-diagnostic co-development. There is very lit-
tle doubt that, in the future, NGS will play a prominent role in
the development of molecular-based targeted cancer drugs, how-
ever, there is still a number of technical, clinical, and regulatory
challenges that needs to be overcome.
The review article by Nicolaides et al. suggests a different
approach to drug-diagnostic co-development (12). Here, they
discuss the use of co-developing diagnostic-targeting vectors to
identify patients whose malignant tissue can specifically take up a
targeted anti-cancer drug vector prior to treatment. Using this sys-
tem, the patients can be predetermined in real-time as to whether
or not their tumors can specifically take up a drug-linked diag-
nostic vector, thus inferring the uptake of a similar vector linked
to an anti-cancer agent. According to the authors, this approach
offers complementary opportunities to the rapid development
of broad tumor-specific agents for use in personalized cancer
medicine.
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Biomarkers may not only serve as an important tool in relation
to development of new molecular-based targeted cancer drugs
through the drug-diagnostic co-development model but also for
repurposing of existing chemotherapeutic anti-cancer drug. The
review article by Stenvang et al. describes a strategy of biomarker-
guided repurposing of chemotherapeutic drugs for cancer therapy
with a specific focus on the topoisomerase I inhibitors and the use
of Top1 as a potential predictive biomarker (13).
The recognition of heterogeneity of cancer diseases has called
for a rethinking of the clinical trial designs used to demonstrate
safety and efficacy of new targeted anti-cancer drugs. The efficacy
of these drugs depends on a specific molecular aberration of the
tumor that the drug-diagnostics co-development model tries to
encounter. In the review by Simon, different clinical trial designs
for the parallel development of drugs and diagnostics are dis-
cussed both with respect to the use of a single biomarker as well
as a genome-wide discovery of a predictive classifier (14).
The development of crizotinib for treatment NSCLC patients
with ALK rearrangement is definitively a landmark in rela-
tion to drug-diagnostic co-development in oncology. This ALK
rearrangement was discovered in 2007 and already in 2011 crizo-
tinib obtained US FDA approval together with the FISH assay for
detection of this specific rearrangement (Vysis ALK Break Apart
FISH Probe Kit, Abbott Molecular). In the Review/Opinion by Ou
et al., the authors discuss the issue of whether the requirements
by the US FDA for the simultaneous co-develop of a CDx will
delay the approval of receptor tyrosine kinase (RTK) inhibitors
for RTK-rearranged NSCLC (15).
Despite great progress in the treatment of cancer achieved with
the use of molecular targeted therapy resistance seems to develop
to virtually all of the drugs at some point in time. One way to
suppress or delay development of resistance might be through the
use of combination therapy. In the review article by Goltsov et al.,
a rational approach to a systematic development of combination
therapies is suggested (16). Based on a joint systems analysis of cel-
lular signaling network response and its sensitivity to drug action
and oncogenic mutations, they describe an in silico method to
analyze the targets of drug combinations.
Resistance is also the issue in the research article by Nielsen
et al. where the authors look into the link between miR-21 expres-
sion and/or cellular localization and resistance to trastuzumab in
HER2 positive patients with breast cancer (17). Tumors from 16
HER2 positive patients who underwent adjuvant treatment with
trastuzumab were analyzed. Eight of these patients were consid-
ered resistant to the treatment. The result of this small study did
not show a link between elevated miR-21 expression and resistance
to adjuvant treatment with trastuzumab. However, more studies
will be needed in order to prove or eliminate the role of miR-21.
In a clinical case study article by Russell et al., tumor profil-
ing for two patients has been described (18). Both patients had
advanced-stage cancer and failed standard treatment. The article
describes how tumor profiling was used together with a systematic
literature review (Caris Molecular Intelligence™) that was used to
identify potential beneficial treatments for the patients resulting
in disease remission in both cases.
The use of molecular diagnostics has given us new insight into
the cancer disease biology, which has enabled development of
new anti-cancer drugs with much more specific and well-defined
mechanisms of action. When this knowledge is translated into the
drug-diagnostic co-development model, remarkable results can
be achieved. Crizotinib is one such example, and a similar or even
more remarkable example is the recent development of ceritinib,
another ALK inhibitor for NSCLC patients with ALK rearrange-
ment. In the spring of 2014, ceritinib obtained an accelerated FDA
approval based on efficacy data from only 163 metastatic NSCLC
patients enrolled in a phase I single-arm, open-label clinical trial
(19). Such a result is only achievable with the use of a CDx that
enables pre-selection of the patients who are likely responders
to the drug, which as for ceritinib resulted in a response rate
above 50% even in a phase 1 trial. Despite the challenges that
anti-cancer drug development faces, especially the development
of resistance to the molecular targeted drugs, the drug-diagnostic
co-development model has shown to be an invaluable tool in
oncology, which definitively point to the future.
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